Cloud computing in Pharmaceutical Market Report 2026

The cloud computing in pharmaceutical market size has grown rapidly in recent years. It will grow from $12.93 billion in 2025 to $15.07 billion in 2026 at a compound annual growth rate (CAGR) of 16.6%. The growth in the historic period can be attributed to increasing adoption of digital data management, growing need for scalable information technology (IT) infrastructure, rising use of cloud for clinical data storage, expansion of pharmaceutical research and development (R&D) activities, and increasing focus on cost-efficient computing systems.

The cloud computing in pharmaceutical market size is expected to see rapid growth in the next few years. It will grow to $27.6 billion in 2030 at a compound annual growth rate (CAGR) of 16.3%. The growth in the forecast period can be attributed to growing demand for AI-enabled drug discovery, rising adoption of hybrid cloud models, increasing shift toward digital pharma manufacturing, expansion of real-world data and analytics usage, and growing need for secure cloud-based compliance systems. Major trends in the forecast period include advancements in AI and machine learning platforms, developments in cloud-based clinical trial technologies, innovations in blockchain-enabled data security, research and development in automated pharmaceutical workflows, and advancements in big data analytics for drug development.

The increasing need for personalized healthcare solutions is anticipated to drive the expansion of cloud computing in pharmaceutical applications in the coming years. Personalized medicine is a healthcare strategy that customizes treatments for individual patients by considering their genetic makeup, environmental influences, and lifestyle factors to achieve better outcomes and improved quality of care. This growing demand is largely driven by progress in genomic technologies, which allow for accurate identification of genetic differences and the development of targeted therapies for individuals. Cloud computing supports personalized medicine by offering scalable platforms for storing and processing vast amounts of patient, genomic, and clinical data. It enhances treatment precision and accelerates development timelines by enabling advanced analytics, real-time data sharing, and data-driven drug discovery aligned with individual patient characteristics. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable rise compared with 12 approvals in 2022. As a result, the growing emphasis on personalized medicine is contributing significantly to the advancement of cloud computing adoption in the pharmaceutical sector.

Major companies operating in the cloud computing in pharmaceutical space are focusing on developing advanced unifying platforms to enhance data security, regulatory compliance, and operational efficiency across scientific software environments. A unifying platform brings multiple tools, functions, and services into a single integrated interface; for instance, in April 2024, Certara Inc., a US-based provider of model-informed drug development software, launched Certara Cloud, which integrates its extensive portfolio of scientific software solutions and allows customers to access and manage licensed products from discovery to submission through a single login, improving user experience and accelerating time-to-insight. The platform also strengthens the company’s end-to-end scientific software ecosystem through centralized security and IT administration, embedding unified security controls that enhance data integrity, simplify regulatory compliance, and support secure collaboration across the drug development lifecycle from early research to regulatory submission.

In April 2024, Bayer AG, a Germany-based life sciences and pharmaceutical company, collaborated with Google Cloud to create generative AI-driven healthcare applications centered on radiology. Through this collaboration, Bayer leverages Google Cloud’s advanced artificial intelligence capabilities, including Vertex AI, to develop an innovation platform that supports radiologists in processing and interpreting large volumes of medical imaging data. Google Cloud is a US-based technology company that offers cloud computing services and machine learning platforms.

Major companies operating in the cloud computing in pharmaceutical market are Amazon Web Services Inc., Google LLC, Microsoft Corporation, Alibaba Group Holding Ltd., Dell Technologies Inc., Tencent Holdings Ltd., Accenture plc, International Business Machines Corporation, Cisco Systems Inc., Oracle Corporation, Salesforce Inc., SAP SE, Hewlett Packard Enterprise Company, Capgemini SE, Cognizant Technology Solutions Corporation, DXC Technology Company, Akamai Technologies Inc., Snowflake Inc., CareCloud Inc., ClearDATA Networks Inc.

North America was the largest region in the cloud computing in pharmaceutical market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cloud computing in pharmaceutical market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cloud computing in pharmaceutical market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have influenced the cloud computing in pharmaceutical market by increasing the cost of imported hardware, software licenses, and cloud infrastructure services. this has affected the deployment of cloud solutions across pharmaceutical research, manufacturing, and supply chain segments, particularly in regions such as north america and asia-pacific, which rely heavily on imported technologies. while tariffs have posed challenges in cost management and slowed some deployments, they have also incentivized local infrastructure investments and the development of more cost-efficient cloud solutions, ultimately driving innovation in the market.

Cloud computing in the pharmaceutical sector involves providing on-demand access to computing power, data storage, analytical capabilities, and digital platforms that support activities such as research, drug discovery, production, supply chain management, and commercial operations. These cloud-based solutions allow real-time access to data, flexible scalability, improved collaboration, and stronger compliance with regulatory requirements, while also lowering the costs associated with traditional IT infrastructure. By incorporating advanced technologies including big data analytics, artificial intelligence, and machine learning, cloud computing improves operational efficiency, speeds up innovation, and strengthens data-driven decision-making throughout the pharmaceutical value chain.

The main service models of cloud computing in pharmaceuticals include IaaS, PaaS, and SaaS. IaaS provides scalable storage, servers, and networking. Deployment models include public, private, and hybrid clouds. Technologies include AI, analytics, IoT, blockchain, and disaster-recovery tools. Applications include drug discovery, clinical trials, manufacturing, regulatory compliance, and pharmacovigilance, supporting pharmaceutical companies, biotech firms, research bodies, CROs, and academic institutions.

The cloud computing in pharmaceutical market includes revenues earned by entities through cloud-based data management platforms, software-as-a-service (SaaS) solutions, infrastructure-as-a-service (IaaS), platform-as-a-service (PaaS), clinical data storage services, cybersecurity services, digital supply chain solutions, and cloud-hosted research and development tools. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.